examples, the triazole formation is always introduced
in the last step as the final decoration of the previous
intermediates.11
Efficient synthetic approaches that allow selective and
convenient derivatization of this pharmacological privileged
core structure would expand their assessment and value.
Because a variety of 2-substituted-4,5-dihalo-pyridazi-
nones (5) are commercially available or can be easily made,
there has been an ever growing amount of work in the
literature aimed at the selective functionalization of the 4-
and 5-positions.14,15 However, many existing approaches
are either nonregioselective or require stepwise reactions
(sometimes including protection and deprotection) and
separation of intermediates.
Scheme 1. Proposed “Click and Activate” General Approach
An alternative and largely unexplored approach for
incorporating click chemistry into multiple component
condensations would place the CuAAC step in the mid-
stage rather than the final step of the one-pot process.
One obvious advantage of introducing CuAAC click
chemistry earlier is that triazoles are usually chemically
more stable than alkynes or azides, thus resulting in
better compatibility with other reaction components.
More importantly, in our recent medicinal chemistry
program, we observed a subtle activation effect of the
triazole moiety on its neighboring groups in subsequent
transformations. Based on this observation, here we
propose a broader “click and activate” strategy illu-
strated in Scheme 1: After CuAAC click chemistry on
azide 1, the resulting triazole group in 2 allows activation
of the conjugated double bond with a leaving group
toward nucleophilic substitution to give 3 in one pot.
This double bond can be a part of an electron-deficient
aromatic or heteroaromatic ring.
Scheme 3
Here we report a one-pot synthesis of general structure 8
utilizing CuAAC as the key step that allows easy access to
three points of diversity on the pyridazinone scaffold
(Scheme 3). First, a regioselective azide substitution at
the 5-position of 5 is required. Withazide 6, a click reaction
with terminal acetylenes would be expected to give triazole
7 in a highly regioselective manner. As the final step in the
sequence, we reasoned that the formation of the triazole 7
should switch the reactivity of the 4-(chloro) position from
a “neutral” or “deactivated” (as in azide 6) to an “activated”
state toward nucleophilic attack due to the subtle electronic
effect of triazole. We set out to identify the optimal condi-
tions suitable for all elementary transformations to proceed
in a highly organized manner in one pot.
Scheme 2
The solvent effect of the nucleophilic substitution on the
4,5-dihalopyridazinones by amines, alkoxides, and al-
kylthiolates is well documented in terms of regioselec-
tivity.16,17 However, azide substitution on this core has
been studied to a lesser extent in the literature.17 In fact, all
reported examples required heating for extended periods
and favored substitution at the 5-position. To enable our
2-Substituted-4,5-dichloropyridazinone (5) provides an
ideal substrate to explore this approach (Scheme 2). 2,4,5-
Trisubstituted-3(2H)-pyridazinones (4) are well-known
compounds of agrochemical and pharmaceutical inte-
rest.12 Several commercial products containing this scaf-
fold, such as Chloridazon (herbicide),13 Pyridaben (miti-
cide/insecticide),13 and Emorfazone (anti-inflammatory
agent),12c are worth mentioning.
ꢁ
(14) (a) Maes, B. U. W.; R’kyek, O.; Kosmrlj, J.; Lemiere, G. L. F.;
Esmans, E.; Rozenski, J.; Dommisse, R. A.; Haemers, A. Tetrahedron
ꢂ
ꢂ
2001, 57, 1323. (b) Riedl, Z.; Maes, B. U. W.; Monsieurs, K.; Lemiere,
ꢂ
ꢀ
G. L. F.; Metyus, P.; Hajos, G. Tetrahedron 2002, 58, 5645. (c)
ꢀ
Tapolcsanyi, P.; Maes, B. U. W.; Monsieurs, K.; Lemiere, G. L. F.;
Riedl, Z.; Hajos, G.; Van den Driessche, B.; Dommisse, R. A.; Matyus,
ꢂ
ꢀ
ꢀ
(11) For a one-pot, modular synthesis of trisubstituted 1,2,3-triazoles
involving direct arylation after click reaction, see: Ackermann, L.;
Potukuchi, H. K.; Landsberg, D.; Vicente, R. Org. Lett. 2008, 10, 3081.
P. Tetrahedron 2003, 59, 5919.
(15) Wu, B.; Wang, H.-L.; Pettus, L.; Wurz, R. P.; Doherty, E. M.;
Henkle, B.; McBride, H. G.; Saris, C. J. M.; Wong, L. M.; Plant, M. H.;
Sherman, L.; Lee, M. R.; Hsieh, F.; Tasker, A. S. J. Med. Chem. 2010,
53, 6398.
(16) (a) Pilgrim, K. H.; Pollard, G. E. J. Heterocycl. Chem. 1977, 14,
1039. (b) Lyga, J. W. J. Heterocycl. Chem. 1988, 25, 1757.
(17) (a) Kweon, D.-H.; Kang, Y.-J.; Chung, J.-A; Yoon, Y.-J.
J. Heterocycl. Chem. 1998, 35, 819. (b) Chung, H.-A.; Kweon, D.-H.;
Kang, Y.-J.; Park, J.-W.; Yoon, Y.-J. J. Heterocycl. Chem. 1999, 36, 905.
ꢁ
(12) (a) Tisler, M.; Stanovnik, B. Adv. Heterocycl. Chem. 1990, 49,
385. (b) Coates, W. J. In Comprehensive Heterocyclic Chemistry; Ka-
tritzky, A. R, Rees, C. W., Eds.; Pergamon Press: Oxford, 1996; Vol. 6, p 1. (c)
Frank, H.; Heinisch, G. In Progress in Medicinal Chemistry; Ellis, G. P.,
Luscombe, D. K., Eds.; Elsevier Science: Amsterdam, 1990; Vol. 27, p 1. (d)
Frank, H.; Heinisch, G. In Progress in Medicinal Chemistry; Ellis, G. P.,
Luscombe, D. K., Eds.; Elsevier Science: Amsterdam, 1992; Vol. 29, p 141.
(13) BASF Web site.
Org. Lett., Vol. 13, No. 7, 2011
1683